ART OF MEDICINE 2017

 

THE ACTIVITY OF MONOCYTES/MACROPHAGES IN PATIENTS WITH ISCHEMIC CHRONIC HEART FAILURE

 

S.V. Fedorov

Ivano-Frankivsk National Medical University. Ivano-Frankivsk, Ukraine.

 

Abstract

Abstract. Chronic heart failure (CHF) is a complex clinical syndrome that results from any structural or functional impairment of ventricular filling or ejection of blood. It is a major health issue in society today, because it is associated with health, death and consumption of healthcare resources. HF affects approximately 1-2% of adults in developed countries, and prevalence increases markedly with age: 10% in cohort 75 years and older.

The aim of study was to evaluate of functional activity of blood monocytes/macrophages in patients with ischemic CHF by identification of their spontaneous production of cytokines.

Material and methods. 96 patients with CHF of ischemic genesis were observed. The diagnosis was verified by clinical, laboratory and instrumental methods according to European Society of Cardiology recommendations (2013, 2016). Patients were divided into 3 subgroups (according New-York Heart Association (NYHA) functional class (FC) classification of HF): FC II (NYHA) – 27 patients, FC III (NYHA) – 39 patients and FC IV (NYHA) – 30 patients. Control group consist of 30 practically healthy persons. Suspension of monocytes from blood obtained by Recalde H. method. Interleukin 1b (IL-1b), interleukin 6 (IL-6), and interleukin 10 (IL-10 ) levels in culture supernatant were determined using commercial ELISA kits (ProCon, Russia; Amersham Pharmacia Biotech, UK) according to the manufacturer’s instructions. Statistical analyses were performed using the Statistica 12.0 (StatSoft, Tulsa, OK, USA). Statistical significance was assumed at p<0.05.

Results. The in vitro spontaneous production of proinflammatory cytokines IL-1b and IL-6 by monocytes/macrophages in patients with HF was significant higher than in control group: (119.50±4.12) pg/106 cells vs (51.39±3.71) pg/106 cells (p<0.001) and (6.62±0.41) pg/106 cells vs (2.79±0.28) pg/106 cells (p<0.001) respectively. Instead the spontaneous production of anti-inflammatory IL-10 was lower in HF: (3.79±0.41) pg/106 cells vs (5.86±0.76) pg/106 cells (p<0.01). The severity of HF was associated with increased production by monocytes/macrophages of IL-1b and IL-6 and with decreased production of IL-10.

Conclusion. The monocytes/macrophages in patients with ischemic HF are in condition of chronic activation which manifests of overproduction of proinflammatory cytokines and poor secretion of anti-inflammatory IL-10.

 

Key words: chronic heart failure, monocytes/macrophages, cytokine.

 

Full text: PDF (Rus)

References
  1. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. / C.J.L. Murray, T. Vos, R. Lozano [et al.] // Lancet. - 2012. – Vol.  380. – P.  2197-2
  2. O’Flaherty M. Contributions of treatment and lifestyle to declining CVD mortality: why have CVD mortality rates declined so much since the 1960s? / M. O’Flaherty, I. Buchan, S. Capewell // Heart. - 2013. – Vol. 99. – P.  159-1
  3. The social transition of risk factors for cardiovascular disease in the African region: evidence from three cross-sectional surveys in the Seychelles. / S. Stringhini, B. Viswanathan, J. Gédéon [et al.] // Int. J. Cardiol. - 2013. – Vol. 168. –P. 1201-120
  4. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 /J. McMurrey, S. Adamopoulus, S. Anker [et al.] // Heart J. – 2012. – Vol. 33. – P.1787–1847.
  5. The current cost of heart failure to the national health service in UK /S. Stewart, A. Jenkins, S. Buchan [et al.] // Eur. Heart Fail. – 2002. – Vol. 4. – P.361-371.
  6. Force T.L. Heart   failure:  molecules,  mechanisms and  therapeutic targets. / T.L. Force // Circul. - 2007. - Vol. 115. - P. e347-e349.
  7. White blood cell count, C-reactive protein, and incident heart failure in the Atherosclerosis Risk in Communities (ARIC) Study. / Bekwelem, P.L. Lutsey,  L.R. Loehr [et al.] // Ann. Epidemiol. – 2011. – Vol.21. – P. 739-748.
  8. Engström G. Leukocyte count and incidence of hospitalizations due to heart failure. / G. Engström, O. Melander, B. Hedblad // Circ. Heart Fail. - – Vol. 2. – Р.217–222.
  9. White blood cell count and mortality in patients with ischemic and nonischemic left ventricular dysfunction (an analysis of the Studies of Left Ventricular Dysfunction [SOLVD]). / H.A. Cooper, D.E. Exner, M.A. Waclawiw [et al.] // Am. J. - 1999. – Vol. 84. – Р.252–257.
  10. Association between white blood cell count, epicardial blood flow, myocardial perfusion, and clinical outcomes in the setting of acute myocardial infarction: A Thrombolysis In Myocardial Infarction 10 Substudy. / H.V. Barron, C.P. Cannon, S.A. Murphy [et al.] // - 2000. – Vol. 102. – Р. 2329–2334.
  11. Olivares R. Monocyte count: a risk factor for coronary heart disease? / R. Olivares, P. Ducimetiere, J.Claude // Am. J. Epidemiol. - 1993. –Vol. 137. –Р.49–53.
  12. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)/
    Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. // Eur. Heart J. – 2016. – Vol.37. – P.2129-2200.
  13. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)/ J. Perk, G. Bucker, H. Gohlke [et al.] // Eur Heart J. – –Vol. 33 (13). – P. 1635-1701.
  14. Recalde H.R. A simple method of obtaining monocytes in suspension / H.R. Recalde // J. Immunol. Meth. – 1984. – Vol.69. – P.71-77.
  15. Gordon S. Monocyte and macrophage heterogeneity. / S. Gordon, P.R. Taylor // Rev. Immunol. - 2005. – Vol. 5. – P. 953-964.
  16. Polarization profiles of human M-CSF-generated macrophages and comparison of M1-markers in classically activated macrophages from GM-CSF and M-CSF origin. /M. Jaquin, N. Houlbert, O. Fardel [et al.] // Cell Immunol. -2013. – Vol. 281. – P.51-61.
  17. Hilgendorf I. Making a difference: monocyte heterogeneity in cardiovascular disease. / Hilgendorf, F.K. Swirski // Curr. Atheroscler. Rep. - 2012. –Vol.14. –P.450–459.
  18. CD14++CD16+ monocytes independently predict cardiovascular events: a cohort study of 951 patients referred for elective coronary angiography. / K.S. Rogacev, B. Cremers, A.M. Zawada [et al.] // Am. Coll. Cardiol. - 2012. –Vol.60. – P.1512-1520.
  19. CD14++CD16+ monocytes and cardiovascular outcome in patients with chronic kidney disease. / K.S. Rogacev, S. Seiler, A.M. Zawada [et al.] //  Heart J. - 2011. – Vol.32. – P.84-92.
  20. Monocyte subtypes predict clinical course and prognosis in human stroke. / X. Urra, N. Villamor, S. Amaro [et al.] // Cereb. Blood Flow. Metab. -2009. –Vol.29. –P.994-1002.